4//SEC Filing
Title 19 Promis 4
Accession 0001104659-24-085375
CIK 0001374339other
Filed
Aug 1, 8:00 PM ET
Accepted
Aug 2, 4:15 PM ET
Size
18.1 KB
Accession
0001104659-24-085375
Insider Transaction Report
Form 4
Title 19 Promis
Other
Transactions
- Purchase
Tranche A Common Share Purchase Warrants
2024-07-31+465,116→ 465,116 total→ Common Shares (465,116 underlying) - Purchase
Common Shares, no par value
2024-07-31+465,116→ 1,575,629 total - Conversion
Common Shares, no par value
2024-07-31+500,000→ 2,075,629 total - Purchase
Tranche B Common Share Purchase Warrants
2024-07-31+465,116→ 465,116 total→ Common Shares (465,116 underlying) - Purchase
Tranche C Common Share Purchase Warrants
2024-07-31+465,116→ 465,116 total→ Common Shares (465,116 underlying) - Conversion
Series 2 Preferred Shares, no par value
2024-07-31−500,000→ 0 total→ Common Shares (500,000 underlying)
Footnotes (5)
- [F1]On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the ("Offering") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit.
- [F2]The Series 2 Preferred Shares involuntarily converted into Common Shares at a 1:1 ratio upon the closing of the Offering, which was a cumulative qualified equity financing in excess of $14 million.
- [F3]Consists of 465,116 Tranche A purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche A purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 18 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310.
- [F4]Consists of 465,116 Tranche B purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche B purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 30 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310.
- [F5]Consists of 465,116 Tranche C purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.50 per warrant share. These warrants are currently exercisable and expire on July 31, 2029.
Documents
Issuer
ProMIS Neurosciences Inc.
CIK 0001374339
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0002005531
Filing Metadata
- Form type
- 4
- Filed
- Aug 1, 8:00 PM ET
- Accepted
- Aug 2, 4:15 PM ET
- Size
- 18.1 KB